Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 10/20 | 0.61 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012504 | 0.93 | PTGER4 (0.58) | PTGER4PTGER2MRGPRX4PTGER1PTGDR | |
| SCHEMBL4014640 | 0.92 | PTGER4 (0.72) | PTGER4PTGER2MRGPRX4PTGER1PTGDR | |
| SCHEMBL4015739 | 0.92 | PTGER4 (0.56) | PTGER4PTGER2MRGPRX4PTGER1PTGDR | |
| SCHEMBL4014045 | 0.90 | PTGER4 (0.61) | PTGER4PTGER2PTGER1LMNAMEN1 | |
| SCHEMBL4014779 | 0.89 | PTGER4 (0.53) | PTGER4PTGER2MRGPRX4PTGER1LMNA | |
| SCHEMBL4019942 | 0.88 | PTGER4 (0.53) | PTGER4PTGER2MRGPRX4PTGER1MEN1 | |
| SCHEMBL4012473 | 0.86 | PTGER4 (0.57) | PTGER4PTGER2MRGPRX4PTGER1LMNA | |
| SCHEMBL4014065 | 0.85 | PTGER4 (0.56) | PTGER4PTGER2PTGER1LMNAMEN1 | |
| SCHEMBL4012493 | 0.85 | PTGER4 (0.56) | PTGER4PTGER2PTGER1MEN1KMT2A | |
| SCHEMBL5367029 | 0.85 | PTGER4 (0.57) | PTGER4PTGER2PTGDRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756043-B1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | RAQUALIA PHARMA INC (JP) | 2009-07-01 | — | — | EP | disclosed |
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| EP-1756043-A1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050250818-A1 | Ortho substituted aryl or heteroaryl amide compounds | PFIZER INC | 2005-11-10 | — | — | US | disclosed |
| WO-2005105733-A1 | ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250818-A1 | Ortho substituted aryl or heteroaryl amide compounds | OPRL1, PTGER1, OPRM1 | PTGER4 19/4885PTGER2 6/4885MRGPRX4 105/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | PTGER4 1/4885PTGER2 2/4885MRGPRX4 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.